3SBio (FRA:83B) Loans Receivable: €0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:83B 3SBio Inc FRA:83B
89 GF Score
Price €1.85
GF Value €1.43
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is 3SBio Loans Receivable?

3SBio FRA:83B 89 Loans Receivable is €0 Mil as of Dec. 2025. GuruFocus rates FRA:83B with a GF Score™ of 89/100 and a GF Value™ of €1.43 (Modestly Overvalued). The stock has 1 warning sign investors should review.

3SBio's Loans Receivable for the quarter that ended in Dec. 2025 was €0 Mil.

3SBio Loans Receivable Historical Data

* Premium members only.

The historical data trend for 3SBio's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

3SBio Loans Receivable Chart

3SBio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

3SBio Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:83B
89GF Score
3SBio Inc FRA:83B
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

3SBio Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of €0 Mil mean?
3SBio (FRA:83B) has a Loans Receivable of €0 Mil as of Dec. 2025. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on 3SBio and its competitors.
Is 3SBio's Loans Receivable too high?
3SBio's current Loans Receivable is €0 Mil. Overall, 3SBio has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's Loans Receivable compare to VRTX and REGN?
3SBio's Loans Receivable of €0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on 3SBio and its competitors. 3SBio's current Loans Receivable is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (FRA:83B) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.43, compared to a current price of €1.85 — trading 29.4% above its estimated fair value. The current Loans Receivable is €0 Mil. 3SBio's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For 3SBio (FRA:83B), the current Loans Receivable is €0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 3SBio (FRA:83B) Overvalued in 2026?

Based on GuruFocus' analysis, 3SBio stock appears to be overvalued. The current stock price of €1.85 is trading 29.4% above its estimated GF Value™ of €1.43. GuruFocus considers 3SBio to be Modestly Overvalued.

Key valuation signals for FRA:83B:

  • Loans Receivable: €0 Mil
  • GF Value™: €1.43 vs. price of €1.85 (29.4% above fair value)
  • GF Score™: 89/100 with 1 warning sign

No single metric tells the full story. See the FRA:83B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

3SBio Business Description

Address No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
89GF Score

Get the complete analysis for FRA:83B

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.85
Price
€1.43
GF Value